These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Pharmacologic circumvention of multidrug resistance. Ford JM; Hait WN Cytotechnology; 1993; 12(1-3):171-212. PubMed ID: 7765325 [TBL] [Abstract][Full Text] [Related]
12. The clinical relevance of multidrug resistance. Bellamy WT; Dalton WS; Dorr RT Cancer Invest; 1990; 8(5):547-62. PubMed ID: 1979932 [No Abstract] [Full Text] [Related]
13. Multidrug resistance: P-glycoprotein and its allies--the elusive foes. Chabner BA; Fojo A J Natl Cancer Inst; 1989 Jun; 81(12):910-3. PubMed ID: 2567356 [No Abstract] [Full Text] [Related]
14. Charles F. Kettering Prize. P-glycoprotein and resistance to anticancer drugs. Ling V Cancer; 1992 May; 69(10):2603-9. PubMed ID: 1348966 [No Abstract] [Full Text] [Related]
18. Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance. Sakata K; Kwok TT; Murphy BJ; Laderoute KR; Gordon GR; Sutherland RM Br J Cancer; 1991 Nov; 64(5):809-14. PubMed ID: 1681885 [TBL] [Abstract][Full Text] [Related]
19. Morphologic alterations in drug sensitive vs. drug resistant cells due to cytostatic application. Dietel M; Seidel A Cancer Treat Rev; 1990 Dec; 17 Suppl A():3-10. PubMed ID: 1982641 [No Abstract] [Full Text] [Related]